Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


In Brief: Neoprobe/USSC

This article was originally published in The Gray Sheet

Executive Summary

Neoprobe/USSC: Firms terminate marketing agreement for Neoprobe's RIGS surgical cancer detection/lymphatic mapping products. Neoprobe and U.S. Surgical Corp. co-developed the technology under a September 1996 agreement which called for USSC to pay the majority of a $5.5 mil. investment to Neoprobe upon U.S. and European approval of the first product, the RIGScan CR49 for colorectal cancer detection, in exchange for receiving exclusive worldwide sales rights (excluding Korea, Thailand, Taiwan and Singapore). A biologics licensing application for the RIGScan CR49, submitted by Neoprobe last December, has yet to be approved by FDA ("The Gray Sheet" July 21, I&W-5)...

Related Content




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts